TNGX Tango Therapeutics, Inc.
XNAS 27.19 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TNGX
$27.19
—
Key stats
$27.19
- 52-Week Range
- $6.69 – $34.39
- YTD
- +204.48%
- IV Rank (30D)
- 86.26
- Straddle Price
- $8.18
- P/C Vol Ratio
- 0.22
- Market Cap
- $4.5B
- Open
- $26.67
- Day Range
- $25.94 – $27.31
- Volume
- 3,119,222
- Prev Close
- $26.98
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.09 |
| Cost of Equity (CAPM) | 11.15% (VRP-adj) |
| WACC | 11.13% |
| Volatility Risk Premium | +87.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -12.1% |
| Book / Price | 28.3% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -268.1% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $23.85 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $23.66 |
| Bollinger Width / SMA20 | 95.3% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $4B |
Peers used for multiples: AXSM, BTSG, ERAS, GH, LQDA, ORKA, ROIV, RVMD
60-Day Conviction
60%
20-Day Fair Value
≈ by Nov 20, 2026
$27.81
α +2.1%
rank 89%
conviction
91%
40-Day Fair Value
≈ by Dec 21, 2026
$27.72
α +1.8%
rank 86%
conviction
56%
60-Day Fair Value
≈ by Jan 19, 2027
$27.72
α +1.7%
rank 87%
conviction
60%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $107.78 | 22% | median 14.1× · 7 peers |
| Peer P/S | $4.44 | 22% | median 10.8× · 5 peers |
| Market Anchor (SMA50) | $23.85 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $25.42 | 56% | 35 strikes · skew +0.31 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $4.5B
- Employees
- 137
- List Date
- 2021-08-11
- CIK
- 0001819133
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- ($0.34) (7 est.)
- Headquarters
- Boston, MA
- Homepage
- https://www.tangotx.com
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -22.03% | -9.71% | 17.74% | -4.79% | 30.01% | 2.24% |
| Feb | -- | -0.65% | -23.65% | -9.36% | -28.87% | -6.70% | -13.85% |
| Mar | -- | -20.04% | -24.04% | -30.59% | -27.89% | 81.44% | -4.22% |
| Apr | -- | -1.74% | -22.02% | 0.79% | 10.16% | 1.89% | -2.18% |
| May | -- | -9.96% | -18.92% | -4.95% | 57.45% | 4.77% | 5.68% |
| Jun | -- | -30.52% | 24.34% | 22.57% | 101.57% | 35.32% | 30.66% |
| Jul | -- | -13.89% | 7.30% | 9.44% | 11.03% | -6.76% | 1.42% |
| Aug | 16.52% | 7.61% | 99.08% | 25.19% | 2.76% | -16.06% | 22.52% |
| Sep | 7.66% | -15.02% | 57.26% | -29.55% | 26.13% | 11.63% | 9.69% |
| Oct | -2.36% | 135.78% | -25.33% | -25.34% | 1.69% | 11.70%* | 16.02% |
| Nov | -19.67% | -4.09% | -7.43% | -23.50% | 36.20% | -- | -3.70% |
| Dec | 9.40% | -6.21% | 27.58% | -20.57% | -14.97% | -- | -0.95% |
| Total | 7.64% | -36.41% | 21.95% | -61.91% | 189.36% | 210.26% | 55.15% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $23.79
SMA 50: $23.89
SMA 200: $21.99
Current: $27.24
EMA 12: $24.41
EMA 26: $24.03
MACD: 0.3754 | Signal: 0.5101
BEARISH
ADX (14): 14.92
RANGE
+DI: 28.93
−DI: 15.49
Momentum Oscillators
RSI (14): 64.42
NEUTRAL
Stoch %K: 93.72
Stoch %D: 78.01
Williams %R: -5.44
Volume & Volatility
BB Upper: $26.86
BB Lower: $20.72
OVERBOUGHT
OBV: 151,225,041
Vol SMA 20: 3,702,808
Vol ROC: -39.17%
ATR: $1.63
True Range: $1.35
HV 20: 66.1%
HV 30: 73.2%
HV 60: 65.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7/10)
Key Drivers and Primary Risks:
- Technical indicators suggest a bearish trend, with MACD indicating a bearish momentum signal.
- Recent news headlines have been mixed, but overall sentiment is neutral.
- High volatility (beta = 1.41) increases the risk of significant price moves.
2-3 Sentence Investment Thesis: We believe TNGX's recent strong performance may be unsustainable due to its high beta and declining trend indicators. While some positive news headlines exist, the bearish momentum signal from MACD suggests a potential reversal.
Recent News Sentiment Impact: The recent executive chair transition announcement had a neutral impact on sentiment, while the public offering announcement was perceived positively. However, overall sentiment remains mixed.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bearish
- Medium-term (1-3 months): Downtrend
- Long-term (3-12 months): Range-bound
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $27.99 (resistance)
- SMA 50: $28.19 (resistance)
- Lower Bollinger Band: $25.69 (support)
Momentum Signals:
- RSI interpretation: Neutral (48.22) - not overbought or oversold
- MACD signal: Bearish momentum signal (-0.06 / Signal: 0.09 / Histogram: -0.14)
- Bollinger Bands position: Mean reversion - price near the middle of the band
Volume Analysis: Volume trends and institutional interest signals:
- On-Balance Volume (OBV): Increasing, indicating a lack of conviction
- Volume Rate of Change: 3.58% - moderate increase in volume
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Executive chair transition and public offering announcements were neutral.
- Positive sentiment around the company's strong performance was present.
Sentiment Assessment: Aggregate news sentiment: Neutral
Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- No specific catalysts identified due to mixed news sentiment
Market Narrative: News aligns with technical signals - bearish momentum signal from MACD and declining trend indicators.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta = 1.41) - high volatility, indicating a more volatile stock than the broader market.
Volatility Regime: Current vs historical volatility levels:
- High volatility - stock moves more than the market
- Historical volatility: HV20 74.7%, HV30 67.9%, HV60 122.3%
Options Market Signals: IV rank, put/call ratios, unusual activity:
- IV Rank: Low (3.4%) - historically low volatility expected
- Current IV: 91.7% - moderate implied volatility
- Expected Move: $6.60 (39 DTE), 7-DTE: $3.70
Downside Protection: Support levels and risk management considerations:
- SMA 20: $27.99 (resistance)
- Lower Bollinger Band: $25.69 (support)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- TNGX is outperforming the market, but not its sector.
Institutional Activity: Volume patterns suggesting institutional interest:
- On-Balance Volume (OBV) increasing - lack of conviction
- Institutional buying/selling: No significant activity identified
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- High correlation with the market (0.18) - not independent of market movements.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $27.99 (resistance)
- Lower Bollinger Band: $25.69 (support)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Upper Bollinger Band: $30.28 (breakout potential)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- No specific catalysts identified due to mixed news sentiment
Risk Management: Stop-loss levels and position sizing considerations:
- Consider a stop-loss at SMA 20 ($27.99) or Lower Bollinger Band ($25.69) depending on risk tolerance.
Please note that this analysis is based on the provided data, and it is not intended to provide personalized investment advice.
Generated
News
All TNGX news →
Earnings History
14 of 14 under expected move
Avg Expected Move
56.38%
Avg Actual Move
7.36%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-11-08 | After-Close | 17.34% | 6.04% | 0.35x | Within |
| 2024-02-07 | After-Close | 19.73% | 4.40% | 0.22x | Within |
| 2024-05-08 | After-Close | 20.61% | 1.77% | 0.09x | Within |
| 2024-08-07 | Pre-Market | 27.47% | 3.22% | 0.12x | Within |
| 2024-11-06 | Pre-Market | 80.12% | 37.45% | 0.47x | Within |
| 2025-01-13 | After-Close | 166.08% | 8.39% | 0.05x | Within |
| 2025-02-27 | After-Close | 56.19% | 5.05% | 0.09x | Within |
| 2025-05-12 | After-Close | 229.01% | 6.87% | 0.03x | Within |
| 2025-08-05 | Pre-Market | 20.86% | 4.86% | 0.23x | Within |
| 2025-10-23 | Pre-Market | 38.68% | 13.05% | 0.34x | Within |
| 2026-01-08 | After-Close | 42.97% | 6.29% | 0.15x | Within |
| 2026-03-05 | After-Close | 34.91% | 0.71% | 0.02x | Within |
| 2026-05-11 | Pre-Market | 22.26% | 2.00% | 0.09x | Within |
| 2026-08-11 | After-Close | 13.10% | 2.89% | 0.22x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TNGX Options Activity & IV Rank
TNGX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 134.4%
7-DTE IV: —
Expected Move: $8.18
7-DTE Move: $8.18
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 864
Put Volume: 187
P/C Volume: 0.216
BULLISH
Call OI: 4,349
Put OI: 4,705
P/C OI: 1.082
Total OI: 9,054
ATM Options Pricing
ATM Call: $3.85
ATM Put: $4.33
Call %: 14.2%
Put %: 15.9%
Chain Summary
Chain Volume: 7,111
Chain OI: 20,299
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 64th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
64%
vs own history
GEX tilt
+0.57
OI-weighted, today
Vanna tilt
+0.46
δ-sensitivity to IV
Charm tilt
-0.55
δ-decay vs time
Vanna tilt +0.46: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.55: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 36 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
100%
+58.0
pts
EXTREME
ATM 135.1% / Wing 193.0%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)86.3HighOct 22
Straddle Price (30 DTE)$8.18Oct 22
Beta Analysis
Risk Metrics
Beta: 1.3008
Alpha: 142.04%
Correlation: 0.1667
R-Squared: 2.8%
Stock Volatility: 99.8%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own TNGX
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $23.4M | #637 of 3138 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $15.5M | #1291 of 3716 | +16.5% | 13F | |
| Point72 Hedge fund Steve Cohen | $9.3M | #780 of 1945 | -44.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $5.7M | #1997 of 6285 | +0.9% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1.1M | #1629 of 4729 | +0.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TNGX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 134,318,721 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$11.18M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.89M | 34.79% | 2026-06-30 |
| 2 | Balyasny Asset Management L.P. | $3.13M | 27.96% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $2.99M | 26.76% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $750.24K | 6.71% | 2026-06-30 |
| 5 | STEMPOINT CAPITAL LP | $175.00K | 1.57% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $131.29K | 1.17% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $115.66K | 1.03% | 2026-06-30 |
3 filers$6.59M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.94M | 44.54% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $1.95M | 29.65% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $1.70M | 25.81% | 2026-06-30 |
TNGX Insider Trading (Form 4)
Latest: 2026-10-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Adam Crystal | President, R&D | Mixed | — | $14.84 | -$520.4K | EDGAR |
| 2026-09-24 | Jessica Newcomb | Principal Accounting Officer | Sell (S) | −8,200 | $24.22 | -$198.6K | EDGAR |
| 2026-09-03 | Adam Crystal | President, R&D | Mixed | — | $13.78 | -$463.5K | EDGAR |
| 2026-08-05 | Adam Crystal | President, R&D | Mixed | — | $16.22 | -$595.1K | EDGAR |
| 2026-07-02 | Adam Crystal | President, R&D | Mixed | — | $17.39 | -$658.5K | EDGAR |
| 2026-06-23 | Robert Azelby | Director | Award (A) | +5,740 | — | EDGAR | |
| 2026-06-08 | Lesley Ann Calhoun | Director | Award (A) | +4,000 | — | EDGAR | |
| 2026-06-08 | Mace Rothenberg | Director | Award (A) | +4,000 | — | EDGAR | |
| 2026-06-08 | John B Ketchum | Director | Award (A) | +4,000 | — | EDGAR | |
| 2026-06-08 | Sung Lee | Director | Award (A) | +570 | — | EDGAR | |
| 2026-06-03 | Adam Crystal | President, R&D | Mixed | — | $14.04 | -$477.2K | EDGAR |
| 2026-05-05 | Matthew Gall | Chief Financial Officer | Award (A) | +40,000 | — | EDGAR | |
| 2026-05-05 | Adam Crystal | President, R&D | Mixed | — | $13.21 | -$432.7K | EDGAR |
| 2026-05-01 | Sung Lee | Director | Award (A) | +12,300 | — | EDGAR | |
| 2026-04-16 | Adam Crystal | President, R&D | Mixed | — | $15.10 | -$761.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TNGX Insider Holdings
18 insiders · @ $27.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Third Rock Ventures IV, L.P. | 10%+ Owner | 14,363,975 | $391.27M | -$58.00M | 7 | 2025-09-17 |
| 2 | TRV GP IV, LLC | 10%+ Owner | 13,386,574 | $364.65M | -$85.23M | 8 | 2025-10-27 |
| 3 | EcoR1 Capital, LLC | 10%+ Owner | 11,836,178 | $322.42M | -$8.44M | 1 | 2024-11-08 |
| 4 | Boxer Capital Management, LLC | 7,432,435 | $202.46M | -$31.54M | 2 | 2024-11-07 | |
| 5 | Aaron I. Davis | Director | 6,799,435 | $185.22M | $5.59M | 8 | 2024-10-28 |
| 6 | Barbara Weber | Director, Executive Chair | 1,629,587 | $44.39M | -$547.1K | 8 | 2026-02-04 |
| 7 | Malte Peters | President & CEO | 367,500 | $10.01M | $0 | 6 | 2026-01-12 |
| 8 | Daniella Beckman | Chief Financial Officer | 184,410 | $5.02M | -$198.7K | 8 | 2026-02-04 |
| 9 | Adam Crystal | President, R&D | 115,743 | $3.15M | -$7.20M | 18 | 2026-10-05 |
| 10 | Jessica Newcomb | Principal Accounting Officer | 66,621 | $1.81M | -$198.6K | 1 | 2026-09-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TNGX Board & Officers
As of SEC filings through Oct 5, 2026Directors 8
- Barbara Weber · since Aug 10, 2021
- Lesley Ann Calhoun · since Aug 10, 2021
- Mace Rothenberg · since Aug 10, 2021
- Malte Peters · since Aug 10, 2021
- John B Ketchum · since Aug 29, 2023
- Kanishka Pothula · since Nov 6, 2023
- Sung Lee · since Jan 2, 2026
- Robert Azelby · since Jun 19, 2026
Officers 4
- Malte Peters · President & CEO · listed since Jan 2026
- Adam Crystal · President, R&D · listed since Feb 2026
- Matthew Gall · Chief Financial Officer · since Apr 15, 2026
- Jessica Newcomb · Principal Accounting Officer · since Apr 15, 2026
10% owners 3
- Third Rock Ventures GP IV, L.P. (entity) · since Aug 10, 2021
- Third Rock Ventures IV, L.P. (entity) · since Aug 10, 2021
- Trv Gp IV, LLC (entity) · since Aug 10, 2021
Changes in the last 10 years (69)
| Jun 19, 2026 | Robert Azelby became a director |
| May 12, 2026 | The company announced the departure of Alexis Borisy from the board in an SEC filing |
| Apr 15, 2026 | Matthew Gall became Chief Financial Officer |
| Apr 15, 2026 | Jessica Newcomb became Principal Accounting Officer |
| Apr 10, 2026 | The company announced the departure of Daniella Beckman as Chief Financial Officer in an SEC filing |
| Feb 4, 2026 | Adam Crystal listed as President, R&D (previously President, Research & Development) in SEC filings |
| Jan 12, 2026 | Malte Peters first listed as President & CEO in an SEC filing |
| Jan 7, 2026 | The company announced the departure of Barbara Weber as Chief Executive Officer in an SEC filing |
| Jan 2, 2026 | Sung Lee became a director |
| Nov 8, 2024 | EcoR1 Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Nov 6, 2023 | Kanishka Pothula became a director |
| Oct 17, 2023 | MVA Investors, LLC no longer listed as a director in SEC filings |
| Oct 17, 2023 | Joseph Lewis no longer listed as a director in SEC filings |
| Oct 17, 2023 | Boxer Capital, LLC no longer listed as a director in SEC filings |
| Oct 17, 2023 | Boxer Asset Management Inc. no longer listed as a director in SEC filings |
| Oct 17, 2023 | Aaron I. Davis no longer listed as a director in SEC filings |
| Oct 13, 2023 | EcoR1 Capital, LLC became a 10% owner |
| Oct 11, 2023 | MVA Investors, LLC first listed as a director in an SEC filing |
| Oct 11, 2023 | Joseph Lewis first listed as a director in an SEC filing |
| Oct 11, 2023 | Boxer Capital, LLC first listed as a director in an SEC filing |
| Oct 11, 2023 | Boxer Asset Management Inc. first listed as a director in an SEC filing |
| Oct 11, 2023 | Aaron I. Davis first listed as a director in an SEC filing |
| Aug 29, 2023 | John B Ketchum became a director |
| Aug 28, 2023 | The company announced the departure of Aaron I. Davis from the board in an SEC filing |
| Aug 15, 2023 | MVA Investors, LLC no longer listed as a 10% owner in SEC filings |
| Aug 15, 2023 | Joseph Lewis no longer listed as a 10% owner in SEC filings |
| Aug 15, 2023 | Boxer Capital, LLC no longer listed as a 10% owner in SEC filings |
| Aug 15, 2023 | Boxer Asset Management Inc. no longer listed as a 10% owner in SEC filings |
| Aug 11, 2023 | Trv Gp Vi, LLC became a director |
| Aug 11, 2023 | Third Rock Ventures VI, L.P. became a director |
| Aug 11, 2023 | Third Rock Ventures GP VI, L.P. became a director |
| Aug 3, 2023 | The company announced the departure of Alan Huang as Chief Scientific Officer in an SEC filing |
| Jun 8, 2023 | Aaron I. Davis no longer listed as a 10% owner in SEC filings |
| Feb 27, 2023 | Adam Crystal became President, Research & Development |
| Dec 1, 2022 | Aaron Weitzman became Chief Medical Officer |
| Oct 13, 2022 | Aaron I. Davis first listed as a 10% owner in an SEC filing |
| Jun 28, 2022 | Aaron I. Davis no longer listed as Chief Executive Officer in SEC filings |
| Feb 3, 2022 | Douglas Barry listed as General Counsel (previously General Counsel, Corporate Secretary) in SEC filings |
| Oct 18, 2021 | Marc Rudoltz became Chief Medical Officer |
| Oct 14, 2021 | Douglas Barry became General Counsel, Corporate Secretary |
| Aug 10, 2021 | Trv Gp IV, LLC became a 10% owner |
| Aug 10, 2021 | Third Rock Ventures IV, L.P. became a 10% owner |
| Aug 10, 2021 | Third Rock Ventures GP IV, L.P. became a 10% owner |
| Aug 10, 2021 | Reid M Huber became a director |
| Aug 10, 2021 | Malte Peters became a director |
| Aug 10, 2021 | Mace Rothenberg became a director |
| Aug 10, 2021 | MVA Investors, LLC became a 10% owner |
| Aug 10, 2021 | Lesley Ann Calhoun became a director |
| Aug 10, 2021 | Joseph Lewis became a 10% owner |
| Aug 10, 2021 | Daniella Beckman became Chief Financial Officer |
| Aug 10, 2021 | Braslyn Ltd. became a 10% owner |
| Aug 10, 2021 | Boxer Capital, LLC became a 10% owner |
| Aug 10, 2021 | Boxer Asset Management Inc. became a 10% owner |
| Aug 10, 2021 | Barbara Weber became a director |
| Aug 10, 2021 | Barbara Weber became Chief Executive Officer |
| Aug 10, 2021 | Alexis Borisy became a director |
| Aug 10, 2021 | Alan Huang became Chief Scientific Officer |
| Oct 6, 2020 | James B Avery became a director |
| Sep 2, 2020 | Richard A. Heyman became a director |
| Sep 2, 2020 | Michael Beauchamp became CFO and Treasurer |
| Sep 2, 2020 | Jamie Christensen became a director |
| Sep 2, 2020 | Christopher Fuglesang became a director |
| Sep 2, 2020 | Christopher Fuglesang became President |
| Sep 2, 2020 | Charles M Baum became a director |
| Sep 2, 2020 | Carole Nuechterlein became a director |
| Sep 2, 2020 | BCTG Holdings, LLC became a 10% owner |
| Sep 2, 2020 | Andrew Ruel Ellis became COO and Secretary |
| Sep 2, 2020 | Aaron I. Davis became a director |
| Sep 2, 2020 | Aaron I. Davis became Chief Executive Officer |
Not reported recently (17)
- Douglas Barry · Last reported as General Counsel in an SEC filing dated Feb 6, 2025
- Trv Gp Vi, LLC · Last reported as a director in an SEC filing dated Aug 22, 2023
- Third Rock Ventures GP VI, L.P. · Last reported as a director in an SEC filing dated Aug 22, 2023
- Third Rock Ventures VI, L.P. · Last reported as a director in an SEC filing dated Aug 22, 2023
- Reid M Huber · Last reported as a director in an SEC filing dated Jun 8, 2023
- Aaron Weitzman · Last reported as Chief Medical Officer in an SEC filing dated Dec 5, 2022
- Braslyn Ltd. · Last reported as a 10% owner in an SEC filing dated Jan 4, 2022
- Marc Rudoltz · Last reported as Chief Medical Officer in an SEC filing dated Nov 3, 2021
- BCTG Holdings, LLC · Last reported as a 10% owner in an SEC filing dated Aug 20, 2021
- James B Avery · Last reported as a director in an SEC filing dated Oct 7, 2020
- Michael Beauchamp · Last reported as CFO and Treasurer in an SEC filing dated Sep 3, 2020
- Andrew Ruel Ellis · Last reported as COO and Secretary in an SEC filing dated Sep 3, 2020
- Carole Nuechterlein · Last reported as a director in an SEC filing dated Sep 3, 2020
- Richard A. Heyman · Last reported as a director in an SEC filing dated Sep 3, 2020
- Jamie Christensen · Last reported as a director in an SEC filing dated Sep 3, 2020
- Christopher Fuglesang · Last reported as a director in an SEC filing dated Sep 3, 2020
- Charles M Baum · Last reported as a director in an SEC filing dated Sep 2, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TNGX Proposed Insider Sales (Form 144)
Latest: 2026-09-22
? Form 144 Guide
Last 30d:
1 filing
· $340K notice value
· Last 90d:
2 filings
· $2.5M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
ADAM CRYSTAL (1, $2.2M) · Jessica Newcomb (1, $340K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-22 | Jessica Newcomb | Officer | 15,231 | $340.1K | 2026-09-22 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-03 | ADAM CRYSTAL | Officer | 81,000 | $2.20M | 2026-08-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-17 | Nextech Crossover I SCSp | Former Affiliate | 3,766,081 | $113.36M | 2026-06-17 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-06-11 | DANIELLA BECKMAN | Officer | 1,791,726 | $51.52M | 2026-06-11 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-10 | DANIELLA BECKMAN | Officer | 4,446 | $133.4K | 2026-06-10 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-05-01 | ADAM CRYSTAL | Officer | 65,460 | $1.42M | 2026-05-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-25 | ADAM CRYSTAL | Officer | 93,000 | $1.81M | 2026-03-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-05 | ADAM CRYSTAL | Officer | 20,251 | $250.1K | 2026-03-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-02-25 | ADAM CRYSTAL | Officer | 54,345 | $700.0K | 2026-02-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-10-23 | Third Rock Ventures IV, L.P. | 10% Stockholder | 477,401 | $3.59M | 2025-10-23 | BTIG, LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
65 ETFs hold TNGX
25 shown · $525.23M total exposure · 0.13% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $115.3M | — | 2026-09-30 |
| 2 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.03% | $107.0M | $10.4B | 2026-10-20 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.12% | $90.2M | $75.1B | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $40.8M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.24% | $32.7M | $13.6B | 2026-10-20 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.25% | $27.0M | $11.0B | 2026-10-20 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.12% | $20.4M | — | 2026-09-30 |
| 8 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.17% | $10.9M | $6.6B | 2026-10-20 |
| 9 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.05% | $10.4M | — | 2026-05-31 |
| 10 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $7.1M | — | 2026-09-30 |
| 11 | FTXH First Trust Nasdaq Pharmaceuticals ETF | First Trust | 0.53% | $6.1M | $1.1B | 2026-10-20 |
| 12 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.02% | $5.9M | — | 2026-10-20 |
| 13 | DWAS Invesco Dorsey Wright SmallCap Momentum ETF | Nport | 1.31% | $5.5M | — | 2026-05-31 |
| 14 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.38% | $5.1M | $1.3B | 2026-10-20 |
| 15 | PTH Invesco Dorsey Wright Healthcare Momentum ETF | Nport | 2.16% | $5.1M | — | 2026-07-31 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $5.0M | $97.4B | 2026-10-20 |
| 17 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.18% | $4.8M | — | 2026-06-30 |
| 18 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.68% | $4.3M | — | 2026-10-21 |
| 19 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.05% | $3.9M | — | 2026-10-20 |
| 20 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.23% | $3.8M | — | 2026-09-30 |
| 21 | USVM VictoryShares US Small Mid Cap Value Momentum ETF | Nport | 0.22% | $3.8M | — | 2026-06-30 |
| 22 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $2.9M | — | 2026-09-30 |
| 23 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.19% | $2.6M | $1.4B | 2026-10-20 |
| 24 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.13% | $2.5M | — | 2026-10-20 |
| 25 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.17% | $2.2M | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.87
TTM Revenue
$53.81M
TTM Net Income
$-123.72M
TTM Op. Cash Flow
$-143.90M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-55.34M | $-0.37 | $-38.87M |
| Q1 '26 | 2026-03-31 | — | $-45.51M | $-0.32 | $-44.36M |
| Q4 '25 | 2025-12-31 | $0.00 | $-38.75M | $-0.30 | $-29.72M |
| Q3 '25 | 2025-09-30 | $53.81M | $15.88M | $0.13 | $-30.95M |
| Q2 '25 | 2025-06-30 | $3.18M | $-38.85M | $-0.35 | $-36.52M |
| Q1 '25 | 2025-03-31 | $5.39M | $-39.88M | $-0.36 | $-41.70M |
| Q4 '24 | 2024-12-31 | $4.12M | $-37.67M | $-0.34 | $-36.65M |
| Q3 '24 | 2024-09-30 | $11.61M | $-29.17M | $-0.27 | $-33.39M |
| Q2 '24 | 2024-06-30 | $19.88M | $-25.55M | $-0.24 | $-23.61M |
| Q1 '24 | 2024-03-31 | $6.47M | $-37.91M | $-0.35 | $-37.86M |
| Q4 '23 | 2023-12-31 | $5.43M | $-30.76M | $-0.30 | $-27.47M |
| Q3 '23 | 2023-09-30 | $10.73M | $-22.26M | $-0.23 | $-31.14M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.58
P/S
68.17
EV/EBITDA
—
EV/Sales
61.75
ROE
-12.1%
ROA
-11.5%
Div Yield
0.00%
FCF Yield
-3.92%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$3.67B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
44.50M
SI % of Float
31.69%
Days to Cover
12.54
Short Vol Ratio
51.1%
Free Float
140.42M
Float %
83.3%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14